What is the appropriate hemodialysis prescription for a hyponatremic patient, including dialysate sodium concentration, ultrafiltration rate, and management of severe symptomatic hyponatremia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hemodialysis Prescription for Hyponatremic Patients

For hyponatremic patients requiring hemodialysis, use a reduced dialysate sodium concentration (130 mEq/L), limit blood flow rate to 50 mL/min, and target a sodium correction rate of no more than 6-8 mEq/L per 24 hours to prevent osmotic demyelination syndrome.

Dialysate Sodium Concentration

  • Set dialysate sodium to 130 mEq/L for patients with severe hyponatremia (serum sodium <120 mEq/L) to prevent overly rapid correction during conventional hemodialysis 1
  • Standard dialysate sodium (typically 140 mEq/L) will correct serum sodium too rapidly and risks osmotic demyelination syndrome in severely hyponatremic patients 2, 1
  • The dialysate sodium concentration should be adjusted daily based on the patient's serum sodium response, gradually increasing toward standard concentrations as serum sodium normalizes 3

Blood Flow Rate and Treatment Duration

  • Limit blood flow rate to 50 mL/min during initial hemodialysis sessions to control the rate of sodium correction, achieving approximately 2 mEq/L/hour rise in serum sodium 1
  • This reduced blood flow rate allows for necessary volume removal and correction of uremia while maintaining safe sodium correction limits 1
  • Monitor serum sodium every 2-4 hours during the initial dialysis treatment to ensure correction does not exceed 6-8 mEq/L in the first 24 hours 4, 1

Alternative: Continuous Venovenous Hemofiltration (CVVH)

  • For patients with severe hyponatremia (serum sodium <100-112 mEq/L) and acute kidney injury, continuous venovenous hemofiltration with low-sodium replacement fluid is the preferred modality 2, 3
  • CVVH allows precise control of sodium correction rate through adjustment of replacement fluid sodium concentration, which can be modified daily based on serum sodium response 2, 3
  • Use single-pool sodium kinetic modeling during CVVH to calculate the exact replacement fluid sodium concentration needed to achieve the desired correction rate 2
  • Two methods exist for adjusting replacement fluid: (1) diluting standard replacement fluid with sterile water, or (2) using custom-compounded low-sodium solutions 2

Correction Rate Guidelines

  • The absolute maximum sodium correction is 8 mmol/L in any 24-hour period for standard-risk patients 4, 5, 6
  • For high-risk patients (cirrhosis, alcoholism, malnutrition, severe hyponatremia), limit correction to 4-6 mmol/L per day with an absolute maximum of 8 mmol/L in 24 hours 4
  • Initial target for the first 24 hours should be 6-8 mEq/L rise in serum sodium, not normalization 2, 1
  • The goal is to raise sodium to 125-130 mEq/L, not to achieve normal sodium levels acutely 5

Management of Severe Symptomatic Hyponatremia

  • For patients with severe neurological symptoms (seizures, altered mental status, coma) requiring urgent dialysis, consider a brief period of 3% hypertonic saline before initiating dialysis to achieve initial 4-6 mEq/L correction over 1-2 hours 4, 5, 6
  • Once symptoms improve, transition to controlled hemodialysis or CVVH with low-sodium dialysate/replacement fluid 2, 3
  • The combined correction from hypertonic saline plus dialysis must still not exceed 8 mmol/L in 24 hours 4, 6

Monitoring Protocol

  • Check serum sodium every 2 hours during the first 6-8 hours of treatment, then every 4-6 hours for the first 24 hours 4, 5
  • Monitor for signs of osmotic demyelination syndrome (dysarthria, dysphagia, oculomotor dysfunction, quadriparesis) which typically occur 2-7 days after rapid correction 4
  • Track fluid removal carefully, as excessive ultrafiltration can concentrate serum sodium beyond the intended correction rate 2

Volume Status Considerations

  • For hypervolemic hyponatremic patients (heart failure, cirrhosis), ultrafiltration goals should be modest initially to avoid concentrating serum sodium too rapidly 2
  • Calculate expected sodium rise from ultrafiltration volume and adjust dialysate sodium accordingly to stay within correction limits 2
  • In anuric patients, all sodium correction will occur through dialysis, requiring even more careful dialysate sodium selection 3

Critical Pitfalls to Avoid

  • Never use standard dialysate sodium (140 mEq/L) in patients with serum sodium <120 mEq/L, as this will cause overly rapid correction and risk osmotic demyelination syndrome 2, 1, 3
  • Do not rely on shortened dialysis time alone to limit sodium correction—this approach is unreliable and may leave the patient inadequately dialyzed 1
  • Avoid aggressive ultrafiltration in the first dialysis session, as volume removal concentrates serum sodium independent of dialysate sodium concentration 2
  • Do not delay necessary dialysis in severely uremic patients out of fear of correcting sodium—use modified dialysate and blood flow rates instead 1, 3

Related Questions

How to manage hyponatremia in patients with Chronic Kidney Disease (CKD) on hemodialysis?
For a stable adult with end‑stage renal disease and serum sodium <130 mmol/L, what is the safest dialysis strategy to correct hyponatremia?
What is the best treatment for a patient with stage 4 kidney disease (Chronic Kidney Disease, CKD) and hyponatremia (low sodium levels)?
Can I give salt tablets to a patient with severe hyponatremia and impaired renal function?
Should a dialysis patient with hyponatremia, on hydralazine, be treated with sodium supplements?
What serum sodium level should a patient have before initiating hemodialysis (HD)?
What is the recommended short‑acting estrogen injection regimen for a menopausal woman with vasomotor symptoms, osteoporosis prevention, or urogenital atrophy, including dosing, need for added progestogen if the uterus is intact, contraindications, monitoring, and non‑hormonal alternatives?
Is the use of petroleum jelly (Vaseline) in the nasal passages recommended?
Which patients should avoid ciprofloxacin?
I am a pre‑menopausal woman with a recent pelvic ultrasound showing a normal‑sized uterus, small nabothian cyst, mild endometrial thickening, non‑visualized ovaries and no adnexal mass, and a thyroid ultrasound showing an atrophic left lobe and several sub‑5 mm benign‑appearing nodules; what is the appropriate next step in management?
What intramuscular testosterone dose (e.g., testosterone enanthate or testosterone cypionate) is recommended for a menopausal woman experiencing low sexual desire, loss of libido, or mild urogenital atrophy who is already on estrogen therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.